Lido Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Lido Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,233	Closed	-$395K	–	1062
2022 Q1	$395K	Buy	+12,233	New	+$375K	﹤0.01%	687
2017 Q2	–	Sell	-5,051	Closed	-$161K	–	280
2017 Q1	$161K	Buy	+5,051	New	+$135K	0.04%	218

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Lido Advisors's SUPN Position: Q2 2022 in Review

Lido Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 12,233 shares — an estimated $395K sold.

Lido Advisors first reported a position in SUPN in Q1 2017 and held it in 2 quarters. The position peaked at $395K in Q1 2022. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

Lido Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Lido Advisors sold 12,233 Supernus Pharmaceuticals shares in Q2 2022, an estimated $395K.
Lido Advisors first reported a position in Supernus Pharmaceuticals in Q1 2017 and held it in 2 quarters.
Lido Advisors's Supernus Pharmaceuticals position peaked at $395K in Q1 2022.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on Lido Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.